rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

Table 2 Bax expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	73.52 ± 0.83ea	56.43 ± 0.74ea	36.47 ± 1.21ea
rAd-p53	5 × 106	0	63.25 ± 1.32ca	53.86 ± 1.54ca	33.71 ± 1.41ca
	5 × 107	0	76.14 ± 0.73ca	59.32 ± 1.45ca	39.47 ± 1.03ca
	5 × 108	0	79.62 ± 1.46ca	64.74 ± 1.08ca	41.35 ± 1.15ca
	5 × 109	0	82.54 ± 1.28ca	69.53 ± 1.02ca	43.75 ± 1.1ca
rAd-p53 + OXA	5 × 106	3.2	78.82 ± 0.88eca	58.64 ± 1.07eca	49.15 ± 1.04eca
	5 × 107	3.2	84.32 ± 1.02eca	62.74 ± 1.19eca	52.9 ± 1.31eca
	5 × 108	3.2	87.41 ± 1.03eca	67.38 ± 1.14eca	55.23 ± 1.06eca
	5 × 109	3.2	89.71 ± 0.36eca	75.14 ± 1.65eca	58.67 ± 1.12eca
Control	0	0	26.32 ± 1.04	19.91 ± 0.87	16.74 ± 1.23

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.